JOINN Laboratories (China) Co., Ltd. (Stock Code: 6127) has announced the revision of annual caps related to property management arrangements with Beijing Joinn Biologics. The 2024 Property Service Agreements initially covered the period from 1 September 2024 to 31 December 2026, with past transaction amounts fully exempt from certain connected transaction requirements. However, due to increased demand for electricity and heating and a need to accommodate business growth, the transaction will no longer qualify as fully exempt.

Revised annual caps have been set at RMB6 million for the financial year ending 31 December 2025 and RMB6.5 million for 2026. Historical figures show a transaction amount of RMB0.88 million in 2024 and RMB2.24 million for the nine months ended 30 September 2025. With the highest applicable percentage ratios now exceeding 0.1% but remaining below 5%, the revision triggers reporting, announcement, and annual review obligations under the Listing Rules without requiring a circular or independent shareholders’ approval.

Beijing Joinn Biologics is considered a connected person of the listed entity, as it is held 91.07% by Joinn Biologics (HK) and 8.93% by the Company, with controlling shareholders Ms. Feng and Mr. Zhou holding indirect interests. The Board of JOINN Laboratories (China) Co., Ltd. approved the revised annual caps, citing alignment with normal commercial terms and the Group’s operational needs.